TY  - JOUR
AU  - Spielberg, N.*
AU  - Brimpari, M.*
AU  - Semb, H.
C1  - 65046
C2  - 52265
SP  - A189-A189
TI  - The role of extracellular matrix proteins during in-vitro
      differentiation of Definitive Endoderm (DE) in 3D culture systems.
JO  - Diabetes Technol. Ther.
VL  - 24
PY  - 2022
SN  - 1520-9156
ER  - 

TY  - JOUR
AU  - Bonadonna, R.C.*
AU  - Renard, E.*
AU  - Cheng, A.-L.*
AU  - Fritsche, A.
AU  - Glezer, S.*
AU  - Cali, A.*
AU  - Grisoni, M.L.*
AU  - Umpierrez, G.*
C1  - 48178
C2  - 41084
CY  - New Rochelle
SP  - A31
TI  - Switching to insulin glargine 300 U/ML (GLA-300): Benefits vs GLA-100 by duration of prior basal insulin therapy.
JO  - Diabetes Technol. Ther.
VL  - 18
PB  - Mary Ann Liebert, Inc
PY  - 2016
SN  - 1520-9156
ER  - 

TY  - JOUR
AB  - BACKGROUND: Testing for beta cell autoantibodies is used for wide-scale identification of early stages of type 1 diabetes. This requires suitable screening assays. We aimed to establish screening that utilized a first step assay (3 Screen) able to detect autoantibodies to the target antigens glutamic acid decarboxylase-65 (GAD), insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) to identify children positive for multiple beta cell autoantibodies. METHODS: An ELISA format was used where plates were coated with a mixture of recombinant GAD, IA-2, and ZnT8325W/R-dimer molecules. The performance was determined in venous blood from 686 first-degree relatives of patients with type 1 diabetes, and 200 patients at onset of type 1 diabetes, and applied as a screening assay in capillary blood from 33,639 general population children. RESULTS: The 3 Screen assay sensitivity for detecting autoantibody-positive patients at onset of type 1 diabetes was similar to that achieved by separate radiobinding assays (RBAs) for antibodies to GAD, IA-2, and ZnT8. Results in venous and capillary serum were correlated (R = 0.987). At a threshold corresponding to the 98th centile (29.1 U/mL) of all 33,639 capillary samples, the 3 Screen was positive in 123 samples with two or more RBA-positive antibodies to insulin, GAD, IA-2, or ZnT8, 146 with one antibody, and 479 that were RBA negative for beta cell autoantibodies. CONCLUSION: A 3 Screen ELISA was developed that was suitable for first step screening of multiple beta cell autoantibodies in capillary blood.
AU  - Ziegler, A.-G.
AU  - Haupt, F.
AU  - Scholz, M.
AU  - Weininger, K.
AU  - Wittich, S.
AU  - Löbner, S.
AU  - Matzke, C.
AU  - Gezginci, C.
AU  - Riethausen, S.
AU  - Beyerlein, A.
AU  - Zillmer, S.
AU  - Amoroso, M.*
AU  - Coles, R.*
AU  - Powell, M.*
AU  - Furmaniak, J.*
AU  - Rees Smith, B.*
AU  - Winkler, C.
AU  - Bonifacio, E.
AU  - Achenbach, P.
C1  - 49315
C2  - 41738
CY  - New Rochelle
SP  - 687-693
TI  - 3 screen ELISA for high-throughput detection of beta cell autoantibodies in capillary blood.
JO  - Diabetes Technol. Ther.
VL  - 18
IS  - 11
PB  - Mary Ann Liebert, Inc
PY  - 2016
SN  - 1520-9156
ER  - 

TY  - JOUR
AB  - Abstract Background: We present a pilot study on the feasibility of the application and advantages of online, noninvasive breath gas analysis (BGA) by proton transfer reaction quadrupole mass spectrometry for the screening of gestational diabetes mellitus (GDM) in 52 pregnant women by means of an oral glucose tolerance test (OGTT). Subjects and Methods: We collected and identified samples of end-tidal breath gas from patients during OGTT. Time evolution parameters of challenge-responsive volatile organic compounds (VOCs) in human breath gas were estimated. Multivariate analysis of variance and permutation analysis were used to assess feasibility of BGA as a diagnostic tool for GDM. Results: Standard OGTT diagnosis identified pregnant women as having GDM (n=8), impaired glucose tolerance (n=12), and normal glucose tolerance (n=32); a part of this latter group was further subdivided into a "marginal" group (n=9) because of a marginal high 1-h or 2-h OGTT value. We observed that OGTT diagnosis (four metabolic groups) could be mapped into breath gas data. The time evolution of oxidation products of glucose and lipids, acetone metabolites, and thiols in breath gas after a glucose challenge was correlated with GDM diagnosis (P=0.035). Furthermore, basal (fasting) values of dimethyl sulfide and values of methanol in breath gas were inversely correlated with phenotype characteristics such as homeostasis model assessment of insulin resistance index (R=-0.538; P=0.0002, P(corrected)=0.0034) and pregestational body mass index (R=-0.433; P=0.0013, P(corrected)=0.022). Conclusions: Noninvasive BGA in challenge response studies was successfully applied to GDM diagnosis and offered an insight into metabolic pathways involved. We propose a new approach to the identification of diagnosis thresholds for GDM screening.
AU  - Halbritter, S.
AU  - Fedrigo, M.
AU  - Höllriegl, V.
AU  - Szymczak, W.
AU  - Maier, J.M.
AU  - Ziegler, A.-G.
AU  - Hummel, M.*
C1  - 10847
C2  - 30393
SP  - 917-925
TI  - Human breath gas analysis in the screening of gestational diabetes mellitus.
JO  - Diabetes Technol. Ther.
VL  - 14
IS  - 10
PB  - Mary Ann Liebert Inc.
PY  - 2012
SN  - 1520-9156
ER  - 

TY  - JOUR
AB  - AIMS: Recent advances in analytical technology allow the detection of several hundred volatile organic compounds (VOCs) in human exhaled air, many of which reflect unidentified endogenous pathways. This study was performed to determine whether a breath gas analysis using proton transfer reaction-mass spectrometry (PTR-MS) could serve as a noninvasive method to distinguish between patients with type 2 diabetes mellitus and healthy controls. METHODS: Breath and room air samples were measured from 21 patients with insulin-treated type 2 diabetes and 26 healthy controls. VOCs in the mass range of 20-200 atomic mass units were analyzed using PTR-MS. RESULTS: We identified eight masses characteristic of endogenous VOCs that showed significant differences in the gas profiles of patients with type 2 diabetes and healthy control subjects. Using these VOCs for linear discriminant analysis, the sensitivity and specificity were found to be 90% and 92%, respectively. CONCLUSIONS: These results suggest that it is possible to separate patients with diabetes mellitus type 2 from healthy controls by multivariate analysis of exhaled endogenous VOCs. This is a first step towards the development of a noninvasive test using breath gas of at-risk persons and making it an attractive option for large-scale testing of at-risk populations. However, the establishment of exhaled volatiles as metabolic markers requires additional confirmatory investigations.
AU  - Greiter, M.
AU  - Keck, L.
AU  - Siegmund, T.*
AU  - Hoeschen, C.
AU  - Oeh, U.
AU  - Paretzke, H.G.
C1  - 4491
C2  - 27660
SP  - 455-463
TI  - Differences in exhaled gas profiles between patients with type 2 diabetes and healthy controls.
JO  - Diabetes Technol. Ther.
VL  - 12
IS  - 6
PB  - Mary Ann Liebert, Inc.
PY  - 2010
SN  - 1520-9156
ER  -